Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy

NCT03115424 on ClinicalTrials.gov · last registry update 2024-09-27

A small phase 3 — 46 participants, against a typical 424. The sponsor logged completion for 4 October 2023. Primary outcome, as filed: Weight. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Mayo Clinic
Sponsor type: Other
Enrollment: 46
Started: 2017-06-22
Primary completion: 2023-10-04 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Weight

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.